Aptar Reports Third Quarter 2023 Results

AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong operational performance driven by continued growth of the company’s proprietary drug delivery systems. Strong sales from prestige and mass fragrance dispensing devices also contributed positively to the results. Reported sales increased by 7% and core sales, excluding currency and acquisition effects, increased by 2%. Aptar reported net income of $84 million for the quarter, a 55% increase over the prior year.

Commenting on the third quarter results, Stephan B. Tanda, Aptar President and CEO, said, “Aptar delivered another quarter of strong, double-digit EPS growth, driven by increased core sales in our proprietary pharma dosing and dispensing systems and the success of our beauty dispensing solutions in fragrance. Our margins also continued to improve thanks to our ongoing focus on cost management and operational leverage.”

Third Quarter 2023 Highlights
*Reported sales increased 7% and net income increased 55% to $84 million
*Core sales increased 2% and adjusted EBITDA of $193 million increased 26% from the prior year
*Pharma proprietary drug delivery systems had double-digit growth across multiple therapeutic applications
*Beauty’s prestige and mass fragrance dispensing technologies had double-digit sales growth
*Reported earnings per share increased about 56% to $1.26 compared to $0.81 in the prior year
*Adjusted earnings per share increased 39% to $1.39 compared to $1.00 in the prior year (including comparable exchange rates)
*Margins continued to expand across all three segments
*Cash flow from operations was $173 million and free cash flow was $97 million, up from $55 million in 2022, a 76% increase
details at: https://www.aptar.com/wp-content/uploads/2023/10/PR-Oct-25-2023-Aptar-Q3-2023-Results.pdf

Related Posts

Aptar Pharma Receives InnoPack 2020 China Award

Aptar Pharma was proud to receive an InnoPack China Award recently, in recognition of Aptar Pharma’s well-established Bag-on-Valve Technology (BOV) Platform, with a special focus on our innovative PureHale® device and Pacifica Duo Actuator. PureHale® is a portable and ready-to-use drug delivery solution designed for upper respiratory care. An industry first, this nebulizer-like device distributes a continuous fine mist to gently cleanse, moisturize and soothe the upper respiratory tract. Aptar Pharma’s Pacifica Duo is a twistable actuator that fulfills two needs in one applicator – spray for gentle application and jet for rinsing -providing flexibility to users.

Silgan Completes Acquisition Of Albéa’s Global Dispensing Business, Further Strengthening Its Closures Franchise

Silgan Holdings Inc. announced that it completed its acquisition of the dispensing business of the Albéa Group. This business is a leading global supplier of highly engineered pumps, sprayers and foam dispensing solutions to major branded consumer goods product companies primarily in the beauty and personal care markets. It operates a global network of 10 plants across North America, Europe, South America and Asia. This business generated sales of approximately $395 million in 2019. The purchase price for this acquisition was $900 million, subject to adjustments outlined in the purchase agreement for this acquisition. The Company funded the purchase price for this acquisition and related costs and expenses through term and revolving loan borrowings under its senior secured credit facility, including a $900 million delayed draw term loan.
Back To Top
×Close search
Search